当前位置：
X-MOL 学术
›
Surg. Infect.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Acute Kidney Injury Risk in Patients Treated with Vancomycin Combined with Meropenem or Cefepime
Surgical Infections ( IF 1.4 ) Pub Date : 2021-04-26 , DOI: 10.1089/sur.2020.105 Matthew S Sussman 1 , Michelle B Mulder 1 , Emily L Ryon 1 , Eva M Urrechaga 1 , Gabriel A Lama 1 , Amritpal Bahga 1 , Sarah A Eidelson 1 , Howard M Lieberman 1 , Carl I Schulman 1 , Nicholas Namias 1 , Kenneth G Proctor 1
Surgical Infections ( IF 1.4 ) Pub Date : 2021-04-26 , DOI: 10.1089/sur.2020.105 Matthew S Sussman 1 , Michelle B Mulder 1 , Emily L Ryon 1 , Eva M Urrechaga 1 , Gabriel A Lama 1 , Amritpal Bahga 1 , Sarah A Eidelson 1 , Howard M Lieberman 1 , Carl I Schulman 1 , Nicholas Namias 1 , Kenneth G Proctor 1
Affiliation
Background: No previous studies have determined the incidence of acute kidney injury (AKI) in trauma patients treated with vancomycin + meropenem (VM) versus vancomycin + cefepime (VC). The purpose of this study was to fill this gap.
中文翻译：
万古霉素联合美罗培南或头孢吡肟治疗患者的急性肾损伤风险
背景：之前没有研究确定用万古霉素 + 美罗培南 (VM) 与万古霉素 + 头孢吡肟 (VC) 治疗的创伤患者中急性肾损伤 (AKI) 的发生率。本研究的目的就是填补这一空白。
更新日期：2021-05-04
中文翻译：
万古霉素联合美罗培南或头孢吡肟治疗患者的急性肾损伤风险
背景：之前没有研究确定用万古霉素 + 美罗培南 (VM) 与万古霉素 + 头孢吡肟 (VC) 治疗的创伤患者中急性肾损伤 (AKI) 的发生率。本研究的目的就是填补这一空白。
京公网安备 11010802027423号